Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bionorica Steers U.S. Consumers To Natural Products Through Science

This article was originally published in The Tan Sheet

Executive Summary

Natural product marketer Bionorica looks to science to convince parents about the efficacy of natural remedies for children while they become more aware of possible risks associated with OTC cough and cold formulas

You may also be interested in...



Pediatric Cough/Cold “Reverse Switch” Will Not Increase Safety – CHPA

A potential "reverse switch" of pediatric cough/cold OTC drugs to prescription status would not address concerns about efficacy or misuse of the products, the Consumer Healthcare Products Association says

Over The Counter 1 March 2024: The Emerging Benefits Of ‘Beauty-From-Within,’ Featuring Kenvue’s Paul LaTerra

In this episode of Over the Counter, HBW Insight speaks to Paul LaTerra, Director, R&D, Global Hair and Scalp for Kenvue, a New Jersey-based consumer health company that markets skin care brands Neutrogena, Aveeno and Lubriderm. We discuss growth of the beauty-from-within supplements market, how the products complement topical skin care and hair formulas and the growing body of research demonstrating significant skin and hair health benefits. 

IFF’s New CEO: Commercial Execution Strategy Will Get Biz Back On Track

Under CEO Erik Fyrwald, IFF is committed to improving commercial execution across its four businesses after five years of overall underperformance.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102790

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel